AMLX
Amylyx Pharmaceuticals Inc
NASDAQ: AMLX · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$14.73
-3.09% today
Updated 2026-05-08
Market cap
$1.69B
P/E ratio
—
P/S ratio
0.66x
EPS (TTM)
$-1.48
Dividend yield
—
52W range
$4 – $19
Volume
1.1M
Amylyx Pharmaceuticals Inc (AMLX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $1.43M | $650000.00 | $285000.00 | $22.23M | $380.79M | $87.37M | $0.00 |
| Revenue growth (YoY) | — | -54.4% | -56.2% | +7700.0% | +1612.9% | -77.1% | -100.0% |
| Cost of revenue | $11.90M | $24.59M | $52000.00 | $2.99M | $25.44M | $42.16M | $525000.00 |
| Gross profit | $-10.47M | $-23.94M | $285000.00 | $19.24M | $355.35M | $45.22M | $-525000.00 |
| Gross margin | -734.4% | -3683.7% | 100.0% | 86.5% | 93.3% | 51.8% | — |
| R&D | $11.90M | $24.59M | $44.04M | $93.45M | $128.19M | $104.08M | $90.40M |
| SG&A | $3.08M | $14.86M | $38.93M | $127.13M | $178.86M | $111.63M | $62.89M |
| Operating income | $-13.55M | $-39.01M | $-82.69M | $-201.34M | $38.80M | $-314.73M | $-153.29M |
| Operating margin | -950.5% | -6000.8% | -29013.3% | -905.7% | 10.2% | -360.2% | — |
| EBITDA | $1.11M | $-39.00M | $-82.64M | $-200.85M | $39.89M | $-290.98M | $-144.16M |
| EBITDA margin | 78.1% | -6000.6% | -28995.1% | -903.5% | 10.5% | -333.0% | — |
| EBIT | $-12.44M | $-39.01M | $-82.69M | $-201.34M | $38.80M | $-291.88M | $-144.69M |
| Interest expense | $1.28M | $2.29M | $36000.00 | $4.29M | — | — | — |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-14.82M | $-42.28M | $-87.88M | $-198.38M | $49.27M | $-301.74M | $-144.74M |
| Net income growth (YoY) | — | -185.4% | -107.9% | -125.7% | +124.8% | -712.4% | +52.0% |
| Profit margin | -1039.0% | -6504.6% | -30834.7% | -892.4% | 12.9% | -345.4% | — |